ICLUSIG (ponatinib) patient profiles*
Identifying patients with CP-CML who may be appropriate for ICLUSIG
*Hypothetical patient profiles
ICLUSIG may help patients with distinct clinical features and TKI resistance
Resistant CML
“My diagnosis at 33 years old upended my life. Now I’m trying to survive this chronic disease, with minimal disruption to my daily routine.”
Maddy | 35
Recently engaged entrepreneur
Diagnosis:
CP-CML
Mutations in BCR::ABL:
None
Comorbidities:
None
BCR::ABL1:
16%
Prior Course of Treatment:
dasatinib (18 months), bosutinib (6 months)
Resistant CML
“As someone with a science background, I’m very involved in my CML treatment decisions. I always check each drug’s clinical track record to ensure I’m receiving an effective treatment that’s backed up by long-term data.”
Cynthia | 72
Retired mental health counselor with six grandkids
Diagnosis:
CP-CML
Mutations in BCR::ABL:
None
Comorbidities:
Diabetes (Controlled)
BCR::ABL1:
19%
Prior Course of Treatment:
nilotinib (33 months), dasatinib (15 months)
Mutation-positive CML
"According to my doctor, I just tested positive for a mutation in CML. I'm nervous to find out what this means for my treatment options."
Alan | 49
Chef and avid golfer
Diagnosis:
CP-CML
Mutations in BCR::ABL:
T315I
Comorbidities:
Hypertension (Controlled)
BCR::ABL1:
21%
Prior Course of Treatment:
imatinib (51 months)
ICLUSIG demonstrated efficacy in CML
ICLUSIG shows efficacy in heavily pretreated, TK-resistant patients
BCR::ABL1IS=BCR::ABL1 international scale; CP=chronic phase; CP-CML=chronic phase chronic myeloid leukemia; CML=chronic myeloid leukemia; CV=cardiovascular; TKI=tyrosine kinase inhibitor.